KLRS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
11.8M
-4.6%
12.4M
+4.7%
11.8M
+9.6%
10.8M
-15.2%
12.7M
R&D
8.3M
-7.5%
9.0M
+19.1%
7.6M
+5.8%
7.2M
-21.6%
9.1M
SG&A
3.5M
+2.9%
3.4M
-21.0%
4.3M
+16.9%
3.6M
+0.8%
3.6M
Operating Income
-11811000
+4.6%
-12386000
-4.7%
-11833000
-9.6%
-10801000
+15.2%
-12741000
EBITDA
-11801000
+4.6%
-12376000
-4.7%
-11823000
-9.6%
-10791000
+15.3%
-12738000
Net Income
-11026000
+4.2%
-11515000
-6.1%
-10856000
-8.6%
-9998000
+15.9%
-11894000
EPS (Basic)
$-0.46
+4.2%
$-0.48
-4.3%
$-0.46
+9.8%
$-0.51
+20.3%
$-0.64
EPS (Diluted)
$-0.46
+4.2%
$-0.48
-4.3%
$-0.46
+9.8%
$-0.51
+20.3%
$-0.64
Shares (Diluted)
23.8M
+0.0%
23.8M
+0.3%
23.7M
+20.9%
19.6M
+4.9%
18.7M
Kalaris Therapeutics (KLRS) — Financials